New hope for rare adrenal cancer: immunotherapy trial aims to keep disease at bay

NCT ID NCT07085572

Summary

This study is testing if a drug called cemiplimab can help keep advanced adrenal cancer from getting worse in patients whose disease has responded to initial chemotherapy. The goal is to see if this immunotherapy, given as a maintenance treatment, can delay or prevent the cancer from progressing. The trial is enrolling about 31 adults in Italy who have not seen their cancer worsen after their first round of treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADRENAL CORTICAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • S.C. Oncologia - ASST Spedali Civili di Brescia

    RECRUITING

    Brescia, Brescia, 25123, Italy

Conditions

Explore the condition pages connected to this study.